Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Reimbursement News » Myriad Genetics' Breast Cancer Recurrence Test Refused Expanded Coverage in Draft LCDs

Myriad Genetics' Breast Cancer Recurrence Test Refused Expanded Coverage in Draft LCDs

Jun 09, 2020
|
staff reporter

NEW YORK – Two Medicare Administrative Contractors released draft local coverage determinations last week denying a request from Myriad Genetic Laboratories to expand coverage of its EndoPredict breast cancer gene expression test.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

A Few, as Expected

The US Centers for Disease Control and Prevention has identified a small group of breakthrough COVID-19 cases, the Wall Street Journal reports.

For the Unknown Soldiers

The New York Times reports that the US Department of Defense is to use genetic genealogy approaches to identify the remains of unknown soldiers.

Prep for the Next One

Vox and Nature discuss the importance of preparing for the next pandemic.

Nature Papers Compare CtDNA Assays, Examine Lettuce Domestication, More

In Nature this week: comparison of five circulating tumor DNA assays, resequencing analysis of lettuce gives insight into its domestication, and more.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.